Executive Summary: Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report.

{"article_title":"Executive Summary: Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report.","author":"Stevens SM, Woller SC, Baumann Kreuziger L, Bounameaux H, Doerschug K, Geersing GJ, Huisman MV, Kearon C, King CS, Knighton AJ, Lake E, Murin S, Vintch JRE, Wells PS, Moores LK","journal_title":"Chest","issn":"1931-3543","isbn":"","publication_date":"2021-12-01","volume":"160","issue":"6","first_page":"2247","page_count":"","accession_number":"34352279","doi":"10.1016\/j.chest.2021.07.056","publisher":"Elsevier","doctype":"Journal Article","subjects":"Fibrinolytic Agents therapeutic use; Pulmonary Embolism drug therapy; Thrombolytic Therapy methods; Venous Thrombosis drug therapy; Drug Therapy, Combination; Evidence-Based Medicine; Fondaparinux therapeutic use; Heparin, Low-Molecular-Weight therapeutic use; Humans; Injections, Intravenous; Injections, Subcutaneous; International Normalized Ratio; Risk Assessment; Vitamin K antagonists & inhibitors","interest_area":["Cardiology"," Emergency Medicine"],"abstract":"Background: This is the 2nd update to the 9th edition of these guidelines. We provide recommendations on 17 PICO (Population, Intervention, Comparator, Outcome) questions, four of which have not been addressed previously. Methods: We generate strong and weak recommendations based on high-, moderate-, and low-certainty evidence, using GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) methodology. Results: The panel generated 29 guidance statements, 13 of which are graded as strong recommendations, covering aspects of antithrombotic management of VTE from initial management through secondary prevention and risk reduction of postthrombotic syndrome. Four new guidance statements have been added that did not appear in the 9th edition (2012) or 1st update (2016). Eight statements have been substantially modified from the 1st update. Conclusion: New evidence has emerged since 2016 that further informs the standard of care for patients with VTE. Substantial uncertainty remains regarding important management questions, particularly in limited disease and special patient populations. Copyright \u00a9 2021. Published by Elsevier Inc.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=34352279","isPdfLink":false,"isSAML":false,"an":"34352279","number_other":"","type_pub":"","issn_electronic":"1931-3543","languages":"English","language":"eng","date_entry":"Date Created: 20210805 Date Completed: 20220119 Latest Revision: 20220119","date_update":"20240105","titleSource":"Chest [Chest] 2021 Dec; Vol. 160 (6), pp. 2247-2259. Date of Electronic Publication: 2021 Aug 02.","date_pub_cy":"","type_document":"","contract_publisher":"","authored_on":"2021-12-01","description":"Background: This is the 2nd update to the 9th edition of these guidelines. We provide recommendations on 17 PICO (Population, Intervention, Comparator, Outcome) questions, four of which have not been addressed previously.<br \/>Methods: We generate strong and weak recommendations based on high-, moderate-, and low-certainty evidence, using GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) methodology.<br \/>Results: The panel generated 29 guidance statements, 13 of which are graded as strong recommendations, covering aspects of antithrombotic management of VTE from initial management through secondary prevention and risk reduction of postthrombotic syndrome. Four new guidance statements have been added that did not appear in the 9th edition (2012) or 1st update (2016). Eight statements have been substantially modified from the 1st update.<br \/>Conclusion: New evidence has emerged since 2016 that further informs the standard of care for patients with VTE. Substantial uncertainty remains regarding important management questions, particularly in limited disease and special patient populations.<br \/> (Copyright © 2021. Published by Elsevier Inc.)","upload_link":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&scope=site&db=mdl&AN=34352279&authtype=shib&custid=ns346513&group=main&profile=eds","no_of_pages":"","authored_by":"Stevens SM, Woller SC, Baumann Kreuziger L, Bounameaux H, Doerschug K, Geersing GJ, Huisman MV, Kearon C, King CS, Knighton AJ, Lake E, Murin S, Vintch JRE, Wells PS, Moores LK"}